8-KMaterial AgreementsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Feb 7, 2017)

Filed February 7, 2017For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 7, 2017, to report an amendment to its Credit Agreement, dated February 2, 2017. This amendment is primarily related to the company's planned acquisition of its corporate headquarters and related facilities, a transaction previously disclosed in December 2016. The key update is that the financing for this acquisition, specifically lease financing and other similar arrangements, will not be classified as 'Indebtedness' or 'Capital Lease Obligations' under the existing Credit Agreement. This reclassification is significant for investors as it impacts the calculation of Regeneron's total leverage ratio. By excluding this lease financing from debt calculations, the company maintains flexibility within its debt covenants and may present a more favorable leverage profile. Importantly, as of the filing date, no amounts were outstanding under the Credit Agreement, suggesting this amendment is proactive in anticipation of the facility acquisition and its associated financing.

Key Highlights

  • 1Regeneron amended its Credit Agreement on February 2, 2017, via Consent and Amendment No. 1.
  • 2The amendment addresses the financing for the acquisition of the company's corporate headquarters and related facilities, previously reported in December 2016.
  • 3Key provision: Lease financing and similar arrangements for the acquired facility will not be considered 'Indebtedness' or 'Capital Lease Obligations' under the Credit Agreement.
  • 4This exclusion impacts the calculation of Regeneron's total leverage ratio.
  • 5The amendment aims to provide flexibility within the company's debt covenants.
  • 6No amounts were outstanding under the Credit Agreement as of the filing date (February 7, 2017).

Frequently Asked Questions

The main purpose of this 8-K filing is to report an amendment to Regeneron's existing Credit Agreement. This amendment is specifically to accommodate the planned acquisition of its corporate headquarters and associated facilities and to ensure that the financing for this acquisition is treated favorably under the terms of the Credit Agreement.

The amendment ensures that the lease financing and certain other related arrangements for the acquired facility will not be classified as 'Indebtedness' or 'Capital Lease Obligations' under the Credit Agreement. This means these financing arrangements will not be counted towards Regeneron's total leverage ratio, thereby not increasing its reported debt levels as defined by the agreement.

The filing indicates that as of February 7, 2017, no amounts were outstanding under the Credit Agreement. Therefore, this amendment is a proactive measure related to a future transaction (the facility acquisition) and does not reflect immediate borrowing or outstanding debt under the credit facility at the time of filing.

The acquisition of the corporate headquarters and related facilities was previously reported by Regeneron in its Current Report on Form 8-K filed on December 30, 2016.